Rejection after allogeneic bone marrow transplantation for Fanconi anemia (FA) is a complication with a high risk of mortality. We describe a patient who, following a second episode of rejection after a second allogeneic stem cell transplantation, was successfully treated with antilymphocyte globulin, followed by donor lymphocyte infusion. At three and a half years after donor lymphocyte infusi...

BACKGROUND Transplantation with allogeneic cells has become a promising modality for cancer therapy, which can induce graft-versus-tumor (GVT) effect. This study was aimed at assessing the safety, efficacy, and tissue type GVT (tGVT) response of transplantation with allogeneic skin tumors to treat chemically-induced skin tumors in mice. MATERIAL AND METHODS FVB/N and ICR mice were exposed topic...

Therapy-related myelodysplastic syndrome in patients with acute promyelocytic leukemia is a rare event and the prognosis is poor. Allogeneic bone marrow transplantation is recently being reported as an effective treatment. We present a young patient with acute promyelocytic leukemia who developed myelodysplastic syndrome 52 months after complete remission. She underwent allogeneic peripheral bl...

Peripheral blood progenitor cells (PBPCs) are increasingly being used to replace bone marrow cells (BMCs) as a source of hematopoietic stem cells also in the field of allogeneic transplantation. Whereas it is well known that PBPC grafts and BM differ significantly in progenitor cell content and lymphocyte dose, the clinical consequences of these differences with respect to engraftment, graft-ve...

Although much has been published on the application of autologous and allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma (FL), no uniform consensus exists among physicians on when to use this strategy. Three large randomized trials failed to show a survival benefit using autologous transplantation for FL patients in first complete remission. Similarly, many ...

BACKGROUND The impact on quality of life of allogeneic stem cell transplantation or conventional chemotherapy in patients with acute myeloid leukemia remains unclear, mainly because of a lack of studies with long-term follow-up. The German AML-Intergroup, therefore, initiated a survey on quality of life of patients with a relapse-free survival of at least 5 years after first-line treatment. D...

INTRODUCTION: While allogeneic transplantation has attracted much attention in regenerative medicine, animal models approximating safety and efficacy are continued to be explored in translational research because cell sources and transplantation modalities are diverse. Currently, we are preparing for a clinical study using allogeneic chondrocyte sheets for articular cartilage regeneration. In t...

There is a growing interest in the use of peripheral blood stem cells (PBSC) for allogeneic transplantation. This is due in part to the idea that, as with autologous transplantation, increasing the number of allogeneic hemopoietic progenitors infused may lead to reduced complications. However, introducing the PBSC technique into allogeneic transplants implies theoretical as well as ethical prob...

I N recent years a number of methods have been developed to induce donor-specific transplantation tolerance in adult recipients using bone marrow transplantation. 1-4 One approach. using a mixture of syngeneic and allogeneic bone marrow to prepare allogeneic chimeras (A + B A) has been demonstrated to be effective in achieving longterm donor-specific transplantation tolerance to alloantigens in...

Allogeneic and autologous hematopoietic stem cell transplantations are important therapeutic options for patients with hematologic disorders. Hemostatic complications are frequent after hematopoietic stem cell transplantation with a considerable morbidity and mortality. The incidence of bleedings and thrombosis is highest in the first few weeks after transplantation, but may also occur later. H...